Glenmark Pharma’s research subsidiary– Ichnos Sciences– and  Almirall SA, a global biopharmaceutical company focused on skin health, have announced today that they have entered into an exclusive licensing agreement for ISB 880, the former’s lead molecule IL-1RAP antagonist.  Under the agreement, Almirall is granted global rights to develop and commercialize this monoclonal antibody for autoimmune diseases. Ichnos will retain rights for antibodies acting on the IL-1RAP pathway for oncology indications.